It is plausible that a higher proportion of APOE ε4 carriers are on a path to clinical disease manifestation of AD, putatively driven by the spreading of Tau deposition, which is strongly linked to steeper brain atrophy, memory decline, and short-term clinical diagnosis66. Here, MAPT is linked to Brain atrophy.